OncoMatch

OncoMatch/Clinical Trials/NCT06921837

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

Is NCT06921837 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies BDC-4182 for gastric cancer adenocarcinoma metastatic.

Phase 1/2RecruitingBolt Biotherapeutics, Inc.NCT06921837Data as of Jun 2026Location: Australia · South Korea · Taiwan

Treatment: BDC-4182A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

BDC-4182

Cancer type

Gastric Cancer

Esophageal Carcinoma

Biomarker criteria

Required: CLDN18 expression ≥ 1% of tumor cells IHC ≥ 2+ or Positive (≥ 1% of tumor cells IHC ≥ 2+ or Positive)

If prior Claudin 18 IHC expression is known, the subject must have some degree of Claudin 18 expression as defined as Positive or have expression ≥ 1% of tumor cells IHC ≥ 2+

Disease stage

Required: Stage STAGE 4, STAGE 3

metastatic (Stage 4) or unresectable (Stage 3)

Prior therapy

Max 2 prior lines
Min 1 prior line

Must have received: locally available standard therapies

must have received at least 1-2 prior lines of locally available standard therapies or must be intolerant of standard therapies

Cannot have received: any investigational agent or standard anti-cancer therapies

Any investigational agent or standard anti-cancer therapies within 28 days before starting study treatment or within 5 estimated elimination half-lives, whichever is shorter

Lab requirements

Blood counts

Kidney function

Liver function

Cardiac function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06921837 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior any investigational agent or standard anti-cancer therapies disqualifies patients from enrollment.

Does this trial require CLDN18?

Yes, CLDN18 expression ≥ 1% of tumor cells IHC ≥ 2+ or Positive is a required biomarker for enrollment.

What disease stage is eligible?

Stage STAGE 4 or STAGE 3 is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify